Kornimate/medical-research-clean huggingface dataset:
correlation between occlussion types , in patients with temporomandibular disorders.

Conditions: Temporomandibular Disorder

Summary: study to find if there is correlation between occlusion types and tmd or not

the relationship among occlusion, condylar position and temporomandibular disorders (tmds) has been part of an extensive discussion in the dental field. there is a strong belief that the discrepancy between the centric relation (cr) and the intercuspal position (icp) could predispose to the presence of tmds . it was suggested in the past in the earlier studies that tmd is more common among the individuals who have angle class ii and class iii , malocclusion , open bite , and cross bite . in the 1990s, studies suggested that some occlusal and skeletal characteristics as anterior open bite, unilateral posterior crossbite, overjet greater than 6-7mm, absence of five or more posterior teeth and cr to maximum intercuspation (mi) discrepancy greater than 2mm could be considered occlusal risk factors for tmds . in their study, oyetola et al. reported that 25% of the evaluated tmd patients had malocclusion yet, recently with studies and systematic reviews , this idea ( alocclusion is the main cause of tmd) started to lose its support, and many studies showed that sensitivity to nociceptive stimulations and psychological factors are of more importance in the etiology of tmd

Eligibility criteria:
inclusion criteria: 1. patients above 16 years old and below 50 2. patients with tmd diagnosed (stage 2 wilkes classification , anterior disc displacement with reduction, ) 3. provided informed consent. 4. no history of systemic condition affecting tmj 5. no previous orthodontic ttt exclusion criteria: 1. ear diseases. 2. history of facial trauma. 3. neurological or oncological disease.
a study of orforglipron (ly3502970) in adult participants with obesity or overweight with weight-related comorbidities

Conditions: Obesity; Overweight; Overweight or Obesity

Summary: this study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.


Eligibility criteria:
inclusion criteria: * have a bmi * ≥30.0 kilogram/square meter (kg/m²), * ≥27.0 kg/m² and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening: * hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease (for example, ischemic cardiovascular disease, new york heart association functional class i-iii heart failure). * have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. exclusion criteria: * have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * have a self-reported change in body weight \>5 kg (11 pounds) within 90 days prior to screening. * have family (first-degree relative) or personal history of medullary thyroid cancer (mtc) or multiple endocrine neoplasia (men)2 syndrome. * have had a history of chronic or acute pancreatitis.
group b streptococcus infection and prom incidince

Conditions: Premature Rupture of Fetal Membranes; Group B Streptococcal Infection

Summary: to investigate incidince of prom with gbs infection and role of prophylaxis against it


Eligibility criteria:
inclusion criteria: * pregnant women with prom after 34 wks festation exclusion criteria: * bleeding disorder * emergency conditions
a study of the analgesic (pain-relief) effects of tanezumab in adult patients with diabetic peripheral neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: the purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.

this study was terminated on 18 november 2010 following a us fda clinical hold for the tanezumab diabetic peripheral neuropathy clinical study which halted dosing and enrollment of patients on 19 july 2010 for potential safety issues.

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus (high blood sugar) with hba1c levels of ≤11% at screening, and on a stable anti-diabetic medication regimen for the 30 days prior to randomization. * diagnosis of diabetic peripheral neuropathy pain in the legs or feet with decreased sensation in the feet or decreased/absent ankle jerk/ reflexes. * presence of ongoing pain due to diabetic peripheral neuropathy for at least 3 months. * a pain score of greater than or equal to (≥) 4 for from diabetic peripheral neuropathy on the numerical rating scale (nrs), a 11-point scale with 0 meaning no pain and 10 meaning worst pain at screening. * be willing to stop all pain medications for diabetic peripheral neuropathy except for the limited use of acetaminophen (tylenol) or ibuprofen-like (motrin) medications between screening and baseline and not use prohibited pain medications throughout the duration of the study except as permitted by the study guidelines. exclusion criteria: * painful neuropathies other than diabetic peripheral neuropathy. * other types of diabetic neuropathies. * patients with a past history of carpal tunnel syndrome (cts) with signs or symptoms of cts in the one year prior to screening are not eligible for participation. * patients with fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to severe pain. * patients with a present (current) history of sciatica are not eligible for participation. * the presence of pain conditions that cannot be distinguished from diabetic peripheral neuropathy such as peripheral vascular disease. * amputations dues to diabetes. * patient with any clinically significant medical condition or laboratory abnormalities. * history, diagnosis, or signs and symptoms of clinically significant neurological diseases (such as alzheimer's disease, head trauma, epilepsy or stroke). * history, diagnosis, or signs and symptoms of clinically significant psychiatric diseases (such as bipoar disorder or schizophrenia). * history of known alcohol, analgesic or drug abuse within 2 years of screening. * pregnant women, lactating mothers, women suspected of being pregnant, and women who wish to be pregnant during the course of clinical study.

Keywords: diabetic peripheral neuropathy tanezumab diabetic neuropathies diabetic polyneuropathy diabetic neuropathy painful
continuous infusion of dexamethasone plus tramadol adjunct to morphine pca after abdominal hysterectomy

Conditions: Postoperative Pain; Post Operative Analgesia; Patient-Controlled Analgesia; Abdominal Surgeries

Summary: dexamethasone has been recognized as an antiemetic agent after surgeries, and the combination of dexamethasone and tramadol remained stable in solution up to 5 days. in addition, i.v. basal infusion of tramadol is a certified technique in postoperative pain management. we purposed that combined administration of dexamethasone and tramadol adjunct to i.v. morphine is an effective way in treating postoperative pain.


Eligibility criteria:
inclusion criteria: 1. asa physical status i-ii 2. chinese 3. 19-64yr 4. uterus myoma exclusion criteria: 1. allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records. 2. participants younger than 18yr，older than 65yr or pregnancy was eliminated. 3. due to the significant changes in vital signs might affect cognition of pain and that of sensation, over 20% variation of these records from the baselines or below 92% of spo2 under 20-40% nasal tube oxygen at any time should be excluded from the study. 4. those who were not willing to or could not finish the whole study at any time. 5. any patient who exhibited a combative or incoherent state of pca analgesia would be excluded from the study.

Keywords: glucocorticoid opioids balanced analgesia
a multiple ascending dose study of bci-838 in healthy volunteers

Conditions: Healthy

Summary: this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of bci-838 and its metabolite bci-632 in healthy male and female subjects.

this study will evaluate the safety and tolerability following oral administration of multiple doses of bci-838 in healthy male and female subjects. the pharmacokinetic profile of multiple oral doses of bci-838 in healthy male and female subjects will also be assessed. in addition, the pharmacodynamic effects of bci-838 on the central nervous system using quantitative electroencephalogram analysis will be studied.

Eligibility criteria:
inclusion criteria: * adult male and female healthy volunteers, 18-55 years of age * body mass index (bmi) between 18.0 to 30.0 kg/m2 inclusive * female subjects must have a negative pregnancy test at screening and admission. females of childbearing potential (not at least 2 years postmenopausal or surgically sterile) must be using a reliable, medically acceptable form of contraception for at least 30 days prior to the screening visit and must agree to continue such use throughout the duration of the study and for 3 months after the final dose of study drug. * good general health as determined by medical history and physical examination with no clinically significant medical findings and no clinically relevant medical or surgical history and no acute or ongoing conditions within the past 30 days * able to participate and willing to give written informed consent and to comply with the study restrictions exclusion criteria: * clinically significant medical abnormality, chronic disease or history or presence of significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or neurological disorder * history or current use of alcohol abuse or drug addiction * participation in a drug study within 60 days prior to drug administration. * participation in more than 3 other drug studies in the 10 months preceding the start of this study * donation or blood loss of more than 50 ml of blood within 60 days prior to the first drug administration. donation of more than 1.5 liters of blood in the 10 months preceding the start of this study * illness within 5 days prior to drug administration

Keywords: metabotropic glutamate receptors 2 and 3 antagonist mglur ketamine bdnf depression major depressive disorder treatment resistant depression mood disorder phase 1 safety, tolerability and pharmacokinetics study
application of ideal binary masking to disordered speech

Conditions: Hearing Loss, Sensorineural; Dysarthria

Summary: dysarthria and hearing loss are communication disorders that can substantially reduce intelligibility of speech and the addition of background noise adds a further challenge. this proposal utilizes an established signal processing technique, currently exploited for improved understanding of speech in noise for listeners with hearing loss, to investigate its potential application to overcome speech-in-noise difficulties for listeners understanding dysarthric speech. successful completion of this project will demonstrate proof-of-concept for the application of this signal processing technique to dysarthric speech in noise, and inform the development of an r01 proposal to perform a large-scale evaluation of the technology, and clinically meaningful implications, in a broad range of disordered speech types and severities.


Eligibility criteria:
inclusion criteria:inclusion criteria for all participants * native speakers of american english * no history of speech or language impairment * no significant prior contact with persons having neurogenic speech disorders inclusion criteria for participants with normal hearing * 18 to 70 years of age * auditory thresholds of 20 db hl or better bilaterally at octave frequencies from 250-8000 hz (if under 55 years of age) * auditory thresholds of 25 db hl or better bilaterally at octave frequencies from 250-4000 hz (if over 55 years of age) inclusion criteria for participants with sensorineural hearing loss * 18 to 90 years of age exclusion criteria: * exclusion criteria for all participants * mild or profound hearing loss * conductive or mixed hearing loss * asymmetric hearing loss * obvious concomitant cognitive or mental impairment * unable to achieve upward of 20% words correct
clinico-biological collection of bone, calcium and growth plate pathologies

Conditions: Bone Disorder

Summary: the aim of this project is to set up a biological and clinical collection of patients with progressive bone, calcium and growth plate pathologies. this collection will provide a better understanding of the mechanisms involved in growth plate and bone damage in these diseases and identify factors predictive of progression and new therapeutic targets.


Eligibility criteria:
inclusion criteria: * children (from birth) with growth plate or bone pathology * patients affiliated to or benefiting from a social security scheme * patients able to receive information about the study and to understand the information form in order to participate in the study. this implies : * mastery of the french language * not being subject to a restriction of rights by the judicial authorities * patients or legal representatives having given their consent to participate in the study (expression of non-opposition). exclusion criteria: * patients under legal protection (guardianship, curatorship or safeguard of justice) * pregnant or breast-feeding women
retrospective observational study on gerd management in general hospitals in korea

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: a retrospective observational study of a current status and its management of gerd (gastroesophageal reflux disease) in general hospitals in korea

this study is designed as a multicenter, retrospective observational study. after signing a contract with the research institution or investigator, patients who meet the inclusion/exclusion criteria in the study protocol will be enrolled. the registration of patients at each research site will be carried out in order based on the most recent visit date (or gerd diagnosis date) as of january 1, 2018. data from the study subjects will be collected by reviewing medical records from january 1, 2018, to august 31, 2020. these data will be recorded in the ecrf through interviews, examinations, and tests performed under the investigator's judgment during routine clinical practice within this period.

Eligibility criteria:
inclusion criteria: 1. patients aged 19 years or older as of the date of their first visit. 2. patients who visited domestic general hospitals (secondary and tertiary healthcare institutions) at least twice between january 1, 2018, and august 31, 2020, for the diagnosis or treatment of gerd. exclusion criteria: 1. patients with no gerd treatment information recorded in the medical records, even once. 2. patients deemed inappropriate for participation by the investigator (e.g., when the overall gerd diagnosis/treatment information is missing from the medical records).

Keywords: gastroesophageal reflux disease gerd korean patients observational study retrospective observational study
open-label extension treatment with etanercept (tnfr:fc) for participating patients in etanercept (tnfr:fc) clinical trials

Conditions: Rheumatoid Arthritis

Summary: this study was designed to provide all adult and pediatric arthritis patients (placebo and etanercept(tnfr:fc) treated) who have participated in clinical trials with etanercept (tnfr:fc) the opportunity to receive continued treatment with etanercept (tnfr:fc). the primary objective of this study is to examine safety parameters.


Eligibility criteria:
inclusion criteria: * previous enrollment in immunex protocols * no clinically significant adverse events thought to be due to etanercept (tnfr:fc) during previous treatment. * negative serum pregnancy test not more than 14 days before the first dose of study drug in females of childbearing potential. * no more than one nsaid at a dose not greater than the maximum recommended dose and stable for at least two weeks prior to administration of etanercept (tnfr:fc). exclusion criteria: - previous receipt of tnfr:fc (p55), antibody to tnf, anti-cd4 antibody, or diphtheria il-2 fusion protein. * receipt of investigational drugs or biologics (other than tnfr:fc \[p75\]) within 1 month prior to the first dose of etanercept (tnfr:fc) in this study. * receipt of dmards or methotrexate (except patients from 16.0014) within two weeks prior to the first dose of etanercept (tnfr:fc) in this study. * receipt of cyclophosphamide within six months prior to the first dose of (etanercept (tnfr:fc) in this study. * receipt of cyclosporin within two weeks prior to the first dose of etanercept (tnfr:fc) in this study.

Keywords: rheumatoid arthritis, etanercept, long-term safety, enbrel
do hip injections improve short-term biomechanical outcomes in patients with hip pain

Conditions: Hip Pain

Summary: the purpose of this project is to determine the effect of hip injections on hip biomechanics in patients with hip pain.


Eligibility criteria:
inclusion criteria: * osteoarthritis patients with hip pain requiring hip injection * receiving hip injection * bmi \< 35 exclusion criteria: * bmi \> 35 * severely impaired intellectual capacity * dementia, or other neurodegenerative diseases that would preclude appropriate cognitive or physical ability to perform study protocol

Keywords: hip pain
evaluation of dorsal visual stream in patients with schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia patients in comparing to normal controls show decreased ability to identify objects with decreased level of fragmentation, a task that is associated with magnocellular pathway function.


Eligibility criteria:
inclusion criteria: * schizophrenia exclusion criteria: * ophthalomological or neurological problems * left handed

Keywords: schizophrenia cognitive deficites degraded objects magnocellular pathway
a study of brexpiprazole in patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (adt) in patients with major depressive disorder.


Eligibility criteria:
inclusion criteria: * outpatients, or inpatients at the time of informed consent whose treatment status can be successfully shifted to outpatient status before enrollment in the antidepressant treatment period * male and female patients ≥ 20 to \< 65 years of age (at the time of informed consent) * patients who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial * patients with a dsm-5 classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode," and whose current episode has persisted for at least 8 weeks exclusion criteria: * women who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at screening * sexually active male subjects or sexually active female subjects of childbearing potential, who will not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after the final imp administration. for birth control, 2 of the following methods must be used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (iud), oral contraceptives, or condom with spermicide. * patients with a treatment history showing that all antidepressants (including those not used for the current major depressive episode) cannot be tolerated * patients with a history of electroconvulsive therapy * patients with a diagnosis of any of the following diseases according to dsm-5 1. neurocognitive disorders 2. schizophrenia spectrum and other psychotic disorders 3. bipolar and related disorders 4. feeding and eating disorders 5. obsessive-compulsive disorder 6. panic disorder 7. posttraumatic stress disorder
cytoplasmic activated pd-1 car t cells in refractory/relapsed b cell lymphoma

Conditions: Relapsed Non Hodgkin Lymphoma

Summary: evaluation of the safety and efficacy of car19 t cells carrying cytoplasmic activated pd1 in patients with refractory relapsed b-cell lymphoma

although car19 t cell therapy brings hope, the patients with refractory/relapsed b-cell lymphoma is still a problem for the current treatment. there are still some patients with poor therapeutic efficacy, and the efficacy of car19-t cell therapy remains to be improved. basic research shows that there is a synergistic effect between car-t cell therapy and anti-pd1 pathway, and it did have efficacy in clinic. however, the regimen of car19-t cells combined anti-pd1 inhibitors need to be combined with the application of anti-pd1 antibody and culture of cart cells during the treatment, there may be adverse events to pd1 antibodies. in this study, car19t cells carrying cytosolic activated pd1 possess the dual effects of car19t cells and anti-pd1 or anti-pd-l1 antibodies while overcoming the adverse events of anti-pd1 inhibitors, and might have better efficacy than conventional car19t cells plus anti-pd1 or anti-pd-l1 antibody treatment, with fewer side effects.

Eligibility criteria:
inclusion criteria: * 18-70 years old and the expected lifetime \>3 months * refractory/relapsed cd19 positive b cell lymphoma by pathology * ecog score \<2 * measureable lesions according to recist 1.1 * sufficient heart, liver, kidney and bone marrow function (heart: no heart disease or coronary heart disease, patient heart function nyha grade 1-2; liver: tbil ≤ 3uln, ast ≤ 2.5uln, alt ≤ 2.5uln; kidney: cr≤ 1.25uln; bone marrow: wbc ≥ 2.0 × 109/l, hb ≥ 80 g/l, plt ≥ 30 × 109/l) * no serious allergies * no other serious diseases that conflict with this protocol (eg, autoimmune diseases, immunodeficiency, organ transplantation) * no other history of malignancy * no serious mental disorders * women of childbearing age must be negative for blood pregnancy test within 7 days and must take appropriated contraceptive measures during and 3 months after the study * the patient himself agrees to participate in this clinical study and signed the "informed consent" exclusion criteria: * lactating women * severe infectious or viral diseases (hiv positive, syphilis, etc.) * active hepatitis b or c viral hepatitis * patients who used high-dose glucocorticoids within 1 week * participation in other clinical studies in the past 3 months or having been treated with other gene products

Keywords: relapsed/refractory, b cell, lymphoma, car